期刊
MOLECULAR IMAGING AND BIOLOGY
卷 17, 期 3, 页码 384-393出版社
SPRINGER
DOI: 10.1007/s11307-014-0802-8
关键词
Apoptosis; Caspase-3; Cancer; Positron emission tomography
资金
- NIH [K08 EB006702, R33 CA121952]
- Damon Runyon Clinical Investigator Award
We tested whether positron emission tomography (PET) with the caspase-3-targeted isatin analog [F-18]WC-4-116 could image caspase-3 activation in response to an apoptosis-inducing anticancer therapy. [F-18]WC-4-116 uptake was determined in etoposide-treated EL4 cells. Biodistribution studies with [F-18]WC-4-116 and [F-18]ICMT-18, a non-caspase-3-targeted tracer, as well as [F-18]WC-4-116 microPET imaging assessed responses in Colo205 tumor-bearing mice treated with death receptor 5 (DR5)-targeted agonist antibodies. Immunohistochemical staining and enzyme assays confirmed caspase-3 activation. Two-way analysis of variance or Student's t test assessed for treatment-related changes in tracer uptake. [F-18]WC-4-116 increased 8 +/- 2 fold in etoposide-treated cells. The [F-18]WC-4-116 % ID/g also increased significantly in tumors with high caspase-3 enzyme activity (p < 0.05). [F-18]ICMT-18 tumor uptake did not differ in tumors with high or low caspase-3 enzyme activity. [F-18]WC-4-116 uptake in vivo reflects increased caspase-3 activation and may be useful for detecting caspase-3-mediated apoptosis treatment responses in cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据